Brain effects of cannabis - Neuroimaging findings;Efeitos cerebrais da maconha - Resultados dos estudos de neuroimagem

Revista Brasileira de Psiquiatria

Volumn 27, Issue 1, 2005, Pages 70-78

  De Souza Crippa, José Alexandre ^a   Lacerda, Acioly L T ^b   Amaro, Edson ^a   Filho, Geraldo Busatto ^a   Zuardi, Antonio Waldo ^a   Bressan, Rodrigo A ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cannabinoids; Cannabis; Magnetic resonance imaging; Marijuana abuse; Tomography, emission computed; Tomography, emission computed, single photon

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; DOPAMINE; DOPAMINE 2 RECEPTOR; DRONABINOL; FLUORINE 18; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; OXYGEN 15; PLACEBO; TRACER; WATER;

BRAIN ATROPHY; BRAIN BLOOD FLOW; CANNABIS ADDICTION; CINGULATE GYRUS; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ABUSE; DRUG INTOXICATION; FRONTAL LOBE; HUMAN; INSULA; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 16444371869     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-44462005000100016     Document Type: Review

References (76)

1. Watson SJ, Benson JA , Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000;57(6):547-52.
2. Miller LL, Branconnier RJ. Cannabis: effects on memory and the cholinergic limbic system. Psychol Bull. 1983;93(3):441-56.
3. Hollister LE. Health aspects of cannabis. Pharmacol Rev. 1986;38(1):1-20.
4. Chen J, Paredes W, Lowinson JH, Gardner EL. Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol. 1990;190(1-2):259-62
5. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-4. Comment in: Nature. 1990;346(6284):508.
6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561-4. Comment in: Nature. 1990;346(6284):508.
7. Solowij N. Cannabis and cognitive functioning. New York: Cambridge University Press; 1999.
8. Carlini EA. The good and the bad effects of (-) trans-delta-9- tetrahydrocannabinol (Delta(9)-THC) on humans. Toxicon. 2004;44(4):461-7.
9. Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998;21(12):521-8.
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365(6441):61-5.
11. Herkenham MA. Localisation of cannabinoid receptors in brain: Relationship to motor and reward systems. In: Korenman SG, Barchas JD, eds. Biological basis of substance misuse. New York: Oxford University Press; 1993. p.187-200.
12. Iversen L. Cannabis and the brain. Brain. 2003;126(Pt 6):1252-70.
13. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci. 2001;22(11):565-72.
14. D'Souza DC, Kosten TR. Cannabinoid antagonists: a treatment in search of an illness. Arch Gen Psychiatry. 2001;58(4):330-1. Comment in: Arch Gen Psychiatry. 2001;58(4):322-8.
15. D'Souza DC, Kosten TR. Cannabinoid antagonists: a treatment in search of an illness. Arch Gen Psychiatry. 2001;58(4):330-1. Comment in: Arch Gen Psychiatry. 2001;58(4):322-8.
16. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol. 1999;58(4):315-48.
17. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10(8):1665-9.
18. Campbell AM, Evans M, Thomson JL, Williams MJ. Cerebral atrophy in young cannabis smokers. Lancet. 1971;2(7736):1219-24.
19. Zachariah SB. Stroke after heavy marijuana smoking. Stroke. 1991;22(3):406-9.
20. White D, Martin D, Geller T, Pittman T. Stroke associated with marijuana abuse. Pediatr Neurosurg. 2000;32(2):92-4.
21. Geller T, Loftis L, Brink DS. Cerebellar infarction in adolescent males associated with acute marijuana use. Pediatrics. 2004;113(4):e365-70.
22. Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY. Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA. 1977;237(12):1229-30.
23. Kuehnle J, Mendelson JH, Davis KR, New PF. Computed tomographic examination of heavy marijuana smokers. JAMA 1977;237(12):1231-2.
24. Hannerz J, Hindmarsh T. Neurological and neuroradiological examination of chronic cannabis smokers. Ann Neurol. 1983;13(2):207-10.
25. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Ponto LL, Ghoneim MM, et al. Cerebellar hypoactivity in frequent marijuana users. Neuroreport. 2000;11(4):749-53.
26. Wilson W, Mathew R, Turkington T, Hawk T, Coleman RE, Provenzale J. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J Addict Dis. 2000;19(1):1-22.
27. Ward PB, Solowij N, Peters R, Otton J, Chestern G, Grenyer B. An MRI study of brain volumes in long-term cannabis users. J Psychopharmacol. 2002;16(Suppl 3):A56.
28. Arendt M, Munk-Jorgensen P. Heavy cannabis users seeking treatment-prevalence of psychiatric disorders. Soc Psychiatry Psychiatr Epidemiol. 2004;39(2):97-105.
29. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 2002;325(7374):1212-3.
30. Cahn W, Hulshoff Pol HE, Caspers E. van Haren NE, Schnack HG, Kahn RS. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr Res. 2004;67(2-3):305-7.
31. Mathew RJ, Wilson WH. Substance abuse and cerebral blood flow. Am J Psychiatry. 1991;148(3):292-305.
32. Loeber LT, D.A. Y-T. Human neuroimaging of acute and chronic marijuana use: implications for frontocerebellar dysfunction. Human Psychopharmacol Clin Exp. 1999;14:291-304.
33. Mathew RJ, Wilson WH, Tant SR. Acute changes in cerebral blood flow associated with marijuana smoking. Acta Psychiatr Scand. 1989;79(2):118-28.
34. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE. Regional cerebral blood flow after marijuana smoking. J Cereb Blood Flow Metab. 1992;12(5):750-8.
35. Mathew RJ, Wilson WH. Acute changes in cerebral blood flow after smoking marijuana. Life Sci. 1993;52(8):757-67.
36. Mathew RJ, Wilson WH, Humphreys DF, Lowe JV, Wiethe KE. Changes in middle cerebral artery velocity after marijuana. Biol Psychiatry. 1992;32(2):164-9.
37. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87(5):1932-6.
38. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Valentine A, et al. Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication. Psychiatry Res. 1996;67(1):29-38.
39. Mathew RJ, Wilson WH, Coleman RE, Turkington TG, DeGrado TR. Marijuana intoxication and brain activation in marijuana smokers. Life Sci. 1997;60(23):2075-89.
40. Mathew RJ, Wilson WH, Turkington TG, Coleman RE. Cerebellar activity and disturbed time sense after THC. Brain Res. 1998;797(2):183-9.
41. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101-6. Comment in: Br J Psychiatry. 2001;179:270-1.
42. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101-6. Comment in: Br J Psychiatry. 2001;179:270-1.
43. Mathew RJ, Wilson WH, Chiu NY, Turkington TG, Degrade TR, Coleman RE. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand. 1999;100(1):67-75.
44. Mathew RJ, Wilson WH, Turkington TG, Hawk TC, Coleman RE, DeGrado TR, et al. Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res. 2002;116(3):173-85.
45. Ohlsson A, Lindgren JE, Wahlen A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther. 1980;28(3):409-16.
46. Perez-Reyes M, Di Guiseppi S, Davis KH, Schindler VH, Cook CE. Comparison of effects of marihuana cigarettes to three different potencies. Clin Pharmacol Ther. 1982;31(5):617-24.
47. O'Leary DS, Block RI, Flaum M, Schultz SK, Boles Ponto LL, Watkins GL, et al. Acute marijuana effects on rCBF and cognition: a PET study. Neuroreport. 2000;11(17):3835-41.
48. Volkow ND, Gillespie H, Mullani N, Tancredi L, Grant C, Ivanovic M, et al. Cerebellar metabolic activation by delta-9-tetrahydrocannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2- deoxyglucose. Psychiatry Res. 1991;40(1):69-78.
49. O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology. 2002;26(6):802-16.
50. O'Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, et al. Marijuana alters the human cerebellar clock. Neuroreport. 2003;14(8):1145-51.
51. Tunving K, Thulin SO, Risberg J, Warkentin S. Regional cerebral blood flow in long-term heavy cannabis use. Psychiatry Res. 1986;17(1):15-21.
52. Mathew RJ, Tant S, Burger C. Regional cerebral blood flow in marijuana smokers. Br J Addict. 1986;81(4):567-71.
53. Amen DG, Waugh M. High resolution brain SPECT imaging of marijuana smokers with AD/HD. J Psychoactive Drugs. 1998;30(2):209-14.
54. Lundqvist T, Jonsson S, Warkentin S. Frontal lobe dysfunction in long-term cannabis users. Neurotoxicol Teratol. 2001;23(5):437-43.
55. Solowij N, Stephens R, Roffman RA, Babor T. Does marijuana use cause long-term cognitive deficits? JAMA. 2002;287(20):2653-4; author reply 2654. Comment in: JAMA. 1996;21;275(7):521-7.
56. Solowij N, Stephens R, Roffman RA, Babor T. Does marijuana use cause long-term cognitive deficits? JAMA. 2002;287(20):2653-4; author reply 2654. Comment in: JAMA. 1996;21;275(7):521-7.
57. Solowij N, Stephens R, Roffman RA, Babor T. Does marijuana use cause long-term cognitive deficits? JAMA. 2002;287(20):2653-4; author reply 2654. Comment in: JAMA. 1996;21;275(7):521-7.
58. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287(9):1123-31. Comment in: JAMA. 2002;287(9):1172-4.
59. Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287(9):1123-31. Comment in: JAMA. 2002;287(9):1172-4.
60. Block RI, O'Leary DS, Hichwa RD, Augustinack JC, Boles Ponto LL, Ghoneim MM, et al. Effects of frequent marijuana use on memory-related regional cerebral blood flow. Pharmacol Biochem Behav. 2002;72(1-2):237-50.
61. Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage. 2004;23(3):914-20.
62. Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA. Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology. (Berl). In press 2004.
63. Smith AM, Fried PA, Hogan MJ, Cameron I. Effects of prenatal marijuana on response inhibition: an fMRI study of young adults. Neurotoxicol Teratol. 2004;26(4):533-42.
64. Jacobsen LK, Mencl WE, Westerveld M, Pugh KR. Impact of cannabis use on brain function in adolescents. Ann N Y Acad Sci. 2004;1021:384-90.
65. Grlic L. A comparative study on some chemical and biological characteristics of various samples of Cannabis resin. Bull Narc. 1962;14:37-46.
66. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology. (Berl). 1982;76(3):245-50.
67. Zuardi AW, Guimarães FS, Guimarães VMC, Del Bel EA. Cannabidiol. In: Grotenhermen F, ed. Cannabis und cannabinoide. Bern: Verlag Hans Huber; 2001. p. 381-93.
68. Grippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, et al. Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology. 2004;29(2):417-26.
69. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001;107(3):173-7.
70. French ED, Dillon K, Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport. 1997;8(3):649-52.
71. Pope HG, Gruber AJ, Yurgelun-Todd D. progress. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 1475-90.69. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, et al. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem. 1998;70(1):417-23.
72. Pope HG, Gruber AJ, Yurgelun-Todd D. progress. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 1475-90.69. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, et al. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem. 1998;70(1):417-23.
73. Degenhardt L. The link between cannabis use and psychosis: furthering the debate. Psychol Med. 2003;33(1):3-6.
74. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr Res. 2001;49(1-2):1-52.
75. Volkow ND, Fowler JS. Application of imaging technologies in the investigation of drug addiction. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: the fifth generation of progress. Philadelphia: Lippincott Williams and Wilkins; 2002. p. 1475-90.
76. Gatley SJ, Lan R, Volkow ND, Pappas N, King P, Wong CT, et al. Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem. 1998;70(1):417-23.